1. Home
  2. ABVX

as 05-22-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Founded: 2013 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 886.5M IPO Year: N/A
Target Price: $34.20 AVG Volume (30 days): 72.6K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.72 EPS Growth: N/A
52 Week Low/High: $8.00 - $17.02 Next Earning Date: 04-02-2024
Revenue: $5,134,444 Revenue Growth: N/A
Revenue Growth (this year): -79.39% Revenue Growth (next year): 6427.41%

Share on Social Networks: